These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15161361)

  • 1. Renal toxicity after radionuclide therapy.
    Lambert B; Cybulla M; Weiner SM; Van De Wiele C; Ham H; Dierckx RA; Otte A
    Radiat Res; 2004 May; 161(5):607-11. PubMed ID: 15161361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
    Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
    J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Function Assessment During Peptide Receptor Radionuclide Therapy.
    Erbas B; Tuncel M
    Semin Nucl Med; 2016 Sep; 46(5):462-78. PubMed ID: 27553471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks to normal tissues from radionuclide therapy.
    Meredith R; Wessels B; Knox S
    Semin Nucl Med; 2008 Sep; 38(5):347-57. PubMed ID: 18662556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of radiation nephropathy.
    Breitz H
    Cancer Biother Radiopharm; 2004 Jun; 19(3):359-62. PubMed ID: 15285883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies.
    Akizawa H; Arano Y
    Q J Nucl Med; 2002 Sep; 46(3):206-23. PubMed ID: 12134137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.
    Vegt E; Wetzels JF; Russel FG; Masereeuw R; Boerman OC; van Eerd JE; Corstens FH; Oyen WJ
    J Nucl Med; 2006 Mar; 47(3):432-6. PubMed ID: 16513612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
    Bergsma H; Konijnenberg MW; van der Zwan WA; Kam BL; Teunissen JJ; Kooij PP; Mauff KA; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1802-11. PubMed ID: 27160225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.
    Behr TM; Goldenberg DM; Becker W
    Eur J Nucl Med; 1998 Feb; 25(2):201-12. PubMed ID: 9473271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
    van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
    J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted radiotherapy with radiolabeled somatostatin analogs.
    Nicolas G; Giovacchini G; Müller-Brand J; Forrer F
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):187-204, ix-x. PubMed ID: 21349419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
    Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
    J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal dosimetry in peptide radionuclide receptor therapy.
    Siegel JA; Stabin MG; Sharkey RM
    Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: "Patient radiation ID cards".
    Switzer DW
    J Am Coll Radiol; 2005 Jan; 2(1):93. PubMed ID: 17411772
    [No Abstract]   [Full Text] [Related]  

  • 20. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.